Selective endothelin-A versus combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure

Area of Science:

• Cardiovascular Pharmacology
• Heart Failure Research
• Endothelin Receptor Antagonism

Background:

• The comparative efficacy of endothelin-A (ET(A)) receptor blockade versus combined ET(A)-ET(B) receptor blockade in chronic heart failure (CHF) remains incompletely understood.
• Investigating differential effects of receptor blockade is crucial for developing targeted therapies.

Purpose of the Study:

• To compare the hemodynamic and structural effects of selective ET(A) receptor blockade versus combined ET(A)-ET(B) receptor blockade in a rat model of CHF.
• To elucidate the specific contributions of ET(A) and ET(B) receptors to cardiac function and remodeling in heart failure.

Main Methods:

• A rat model of CHF was established using coronary ligation.
• Animals were treated for one month with an ET(A) antagonist (ABT-627), an ET(B) antagonist (A-192621), or a combination of both.
• Doses were calibrated to achieve specific receptor blockade based on pressor and depressor responses to endothelin-1 and sarafotoxin S6c.

Main Results:

• Both ET(A) and combined ET(A)-ET(B) blockade similarly reduced systolic blood pressure; ET(B) blockade alone had no effect.
• Combined ET(A)-ET(B) blockade significantly reduced heart rate, while ET(A) blockade alone did not.
• Both ET(A) and combined ET(A)-ET(B) blockade improved left ventricular (LV) function (fractional shortening, wall thickening) and reduced LV pressures and volumes, whereas all treatments decreased LV collagen accumulation.

Conclusions:

• Chronic blockade of both ET(A) and ET(B) receptors improved systemic hemodynamics and LV function/remodeling comparably to ET(A) blockade alone.
• Combined ET(A)-ET(B) blockade uniquely decreased heart rate, a differential effect whose long-term clinical significance in CHF requires further investigation.